The specialist in commercialising intellectual property has entered a strategic partnership to develop an innovation hub in Cambridge, aiming to accelerate the scale-up and growth of its portfolio companies.
The specialist in commercialising intellectual property has announced its portfolio company Alusid has signed a distribution agreement with an Italian firm to expand its sustainable materials across Europe.
The vaccine developer has reached a key milestone in the development of its African Swine Fever vaccine candidate.
The animal health company has signed an option to license agreement with Frontier IP's portfolio company to develop a vaccine against a pig disease.
The financial services company has disclosed a director's share sale and repurchase transaction.
The asset management company has disclosed that two directors have sold and repurchased shares, with their total holdings unchanged.
The intellectual property commercialization specialist reported a pre-tax loss and challenging market conditions. Despite portfolio progress, potential exits may face delays due to the current economic climate, with limited visibility on organic growth and margins.
The technology company has secured €25 million in Series A funding to accelerate the development and scale-up of its advanced graphene photonics transceivers, which have the potential to transform artificial intelligence and mobile communications.
The technology company has been recognized for its innovative power electronics design that delivers industry-leading energy efficiency.
The asset management firm's portfolio company has entered a collaboration to develop advanced solar technology, securing a significant grant from Innovate UK.